INTERVENTION 1:	Intervention	0
Letrozole	Intervention	1
letrozole	CHEBI:6413	0-9
Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.	Intervention	2
letrozole	CHEBI:6413	44-53
day	UO:0000033	58-61
duration	PATO:0001309	68-76
breast cancer	DOID:1612	209-222
ductal carcinoma in situ	HP:0030075,DOID:0060074	224-248
cancer	DOID:162	216-222
cancer	DOID:162	276-282
INTERVENTION 2:	Intervention	3
Placebo	Intervention	4
Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.	Intervention	5
day	UO:0000033	47-50
letrozole	CHEBI:6413	98-107
letrozole	CHEBI:6413	180-189
duration	PATO:0001309	122-130
breast cancer	DOID:1612	275-288
ductal carcinoma in situ	HP:0030075,DOID:0060074	290-314
cancer	DOID:162	282-288
cancer	DOID:162	342-348
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
At increased risk for the development or recurrence of breast cancer, defined as an estradiol level  9 pg/mL	Eligibility	1
breast cancer	DOID:1612	55-68
estradiol	CHEBI:23965	84-93
No evidence of suspicious or malignant disease, based on the following examinations:	Eligibility	2
disease	DOID:4,OGMS:0000031	39-46
Clinical bilateral breast examination within the past 6 months	Eligibility	3
bilateral	HP:0012832	9-18
breast	UBERON:0000310	19-25
Bilateral* mammogram within 3 months before randomization OR within 30 days after randomization	Eligibility	4
bilateral	HP:0012832	0-9
Pelvic exam normal within the past 5 years	Eligibility	5
General physical exam within the past 6 months NOTE: *Unilateral mammogram of the uninvolved breast for patients with prior invasive breast cancer or ductal carcinoma in situ (DCIS)	Eligibility	6
unilateral	HP:0012833	54-64
breast	UBERON:0000310	93-99
breast	UBERON:0000310	133-139
breast cancer	DOID:1612	133-146
ductal carcinoma in situ	HP:0030075,DOID:0060074	150-174
Bone density scan within 2 standard deviations from normal within the past 30 days	Eligibility	7
Bone density scan  2 standard deviations below normal allowed if approved by the study physician	Eligibility	8
At least 1 breast that has not been previously treated with radiotherapy or surgery (for patients with prior invasive breast cancer or DCIS)	Eligibility	9
breast	UBERON:0000310	11-17
breast	UBERON:0000310	118-124
radiotherapy	OAE:0000235	60-72
surgery	OAE:0000067	76-83
breast cancer	DOID:1612	118-131
Hormone receptor status:	Eligibility	10
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	11
PATIENT CHARACTERISTICS:	Eligibility	12
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	13
age	PATO:0000011	0-3
35 and over	Eligibility	14
Sex	Eligibility	15
Female	Eligibility	16
female	PATO:0000383	0-6
Menopausal status	Eligibility	17
Postmenopausal, defined by any of the following criteria:	Eligibility	18
At least 12 months without spontaneous menstrual bleeding	Eligibility	19
Prior hysterectomy and bilateral salpingo-oophorectomy	Eligibility	20
bilateral	HP:0012832	23-32
55 years of age with a prior hysterectomy with or without oophorectomy	Eligibility	21
age	PATO:0000011	12-15
< 55 years of age with a prior hysterectomy without oophorectomy OR the status of the ovaries is unknown AND follicle-stimulating hormone (FSH) level is in the postmenopausal range	Eligibility	22
age	PATO:0000011	14-17
hormone	CHEBI:24621	130-137
range	LABO:0000114	175-180
Performance status	Eligibility	23
Normal activity must not be restricted for a significant portion of the day	Eligibility	24
day	UO:0000033	72-75
Life expectancy	Eligibility	25
At least 10 years	Eligibility	26
Hematopoietic	Eligibility	27
Complete blood count with differential normal	Eligibility	28
blood	UBERON:0000178	9-14
Prior benign neutropenia allowed provided the granulocyte count is  1,500/mm^3	Eligibility	29
neutropenia	HP:0001875,DOID:1227	13-24
Hepatic	Eligibility	30
Bilirubin normal	Eligibility	31
Alkaline phosphatase normal	Eligibility	32
phosphatase	GO:0016791,BAO:0000295	9-20
SGOT and SGPT normal	Eligibility	33
Renal	Eligibility	34
Creatinine normal	Eligibility	35
creatinine	CHEBI:16737	0-10
Cardiovascular	Eligibility	36
No uncontrolled cardiovascular disease	Eligibility	37
disease	DOID:4,OGMS:0000031	31-38
Other	Eligibility	38
Not pregnant	Eligibility	39
No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix	Eligibility	40
skin cancer	DOID:4159	79-90
carcinoma	HP:0030731,DOID:305	94-103
No osteoporosis	Eligibility	41
osteoporosis	HP:0000939,DOID:11476	3-15
No hyperlipidemia	Eligibility	42
hyperlipidemia	HP:0003077	3-17
No mental health status resulting in cognitive or emotional impairment that would preclude study participation	Eligibility	43
health status	HP:0032319	10-23
PRIOR CONCURRENT THERAPY:	Eligibility	44
Biologic therapy	Eligibility	45
Not specified	Eligibility	46
Chemotherapy	Eligibility	47
Not specified	Eligibility	48
Endocrine therapy	Eligibility	49
More than 30 days since prior AND no concurrent use of any of the following hormonal agents:	Eligibility	50
Estrogen or progesterone replacement therapy	Eligibility	51
estrogen	CHEBI:50114,BAO:0000760	0-8
progesterone	CHEBI:17026	12-24
Oral contraceptives	Eligibility	52
Raloxifene or other plasma estrogen receptor modulators (SERMs)	Eligibility	53
raloxifene	CHEBI:8772	0-10
estrogen	CHEBI:50114,BAO:0000760	27-35
receptor	BAO:0000281	36-44
Androgens (e.g., danazol)	Eligibility	54
danazol	CHEBI:4315	17-24
Luteinizing hormone-releasing hormone (LHRH) analogs (e.g., goserelin or leuprolide)	Eligibility	55
hormone	CHEBI:24621	12-19
hormone	CHEBI:24621	30-37
goserelin	CHEBI:5523	60-69
leuprolide	CHEBI:6427	73-83
Prolactin inhibitors (e.g., bromocriptine)	Eligibility	56
prolactin	CHEBI:81580,GO:0005148	0-9
bromocriptine	CHEBI:3181	28-41
Antiandrogens (e.g., cyproterone)	Eligibility	57
cyproterone	CHEBI:50742	21-32
More than 60 days since prior AND no concurrent tamoxifen	Eligibility	58
tamoxifen	CHEBI:41774	48-57
No prior aromatase inhibitors (for patients with prior invasive breast cancer or DCIS)	Eligibility	59
breast cancer	DOID:1612	64-77
No concurrent phytoestrogenic dietary supplements (e.g., soy, ginseng, or other natural products)	Eligibility	60
Dietary soy allowed	Eligibility	61
Radiotherapy	Eligibility	62
radiotherapy	OAE:0000235	0-12
See Disease Characteristics	Eligibility	63
disease	DOID:4,OGMS:0000031	4-11
Surgery	Eligibility	64
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	65
disease	DOID:4,OGMS:0000031	4-11
No prior bilateral mastectomy	Eligibility	66
bilateral	HP:0012832	9-18
Other	Eligibility	67
More than 60 days since prior treatment for invasive breast cancer or DCIS	Eligibility	68
breast cancer	DOID:1612	53-66
More than 30 days since prior bisphosphonates or calcitonin	Eligibility	69
calcitonin	CHEBI:3306	49-59
No prior or concurrent participation on a treatment study for invasive breast cancer or DCIS	Eligibility	70
breast cancer	DOID:1612	71-84
No concurrent participation in any other cancer prevention study or osteoporosis prevention study involving pharmacologic agents	Eligibility	71
cancer	DOID:162	41-47
osteoporosis	HP:0000939,DOID:11476	68-80
No concurrent calcitonin	Eligibility	72
calcitonin	CHEBI:3306	14-24
No concurrent bisphosphonate therapy	Eligibility	73
Concurrent cholecalciferol (vitamin D) and calcium to augment bone mineral density allowed	Eligibility	74
vitamin d	CHEBI:27300	28-37
calcium	CHEBI:22984,BAO:0000874	43-50
bone mineral density	CMO:0001226	62-82
Outcome Measurement:	Results	0
Change in Lumbar Density From Baseline to 12 Months	Results	1
The bone mineral density (BMD) test was comprised of the following 4 measurements [total density (g/cm^2)]: lumbar, femoral neck, trochanter, hip.	Results	2
bone mineral density	CMO:0001226	4-24
neck	GO:0044326,UBERON:0000974	124-128
hip	UBERON:0001464	142-145
Time frame: Evaluation occurred at treatment initiation (BL) and after 12-months of treatment.	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Letrozole	Results	5
letrozole	CHEBI:6413	17-26
Arm/Group Description: Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.	Results	6
letrozole	CHEBI:6413	67-76
day	UO:0000033	81-84
duration	PATO:0001309	91-99
breast cancer	DOID:1612	232-245
ductal carcinoma in situ	HP:0030075,DOID:0060074	247-271
cancer	DOID:162	239-245
cancer	DOID:162	299-305
Overall Number of Participants Analyzed: 29	Results	7
Median (Full Range)	Results	8
median	BAO:0002174	0-6
range	LABO:0000114	13-18
Unit of Measure: g/cm^2  -0.036        (-0.092 to 0.272)	Results	9
Results 2:	Results	10
Arm/Group Title: Placebo	Results	11
Arm/Group Description: Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.	Results	12
day	UO:0000033	70-73
letrozole	CHEBI:6413	121-130
letrozole	CHEBI:6413	203-212
duration	PATO:0001309	145-153
breast cancer	DOID:1612	298-311
ductal carcinoma in situ	HP:0030075,DOID:0060074	313-337
cancer	DOID:162	305-311
cancer	DOID:162	365-371
Overall Number of Participants Analyzed: 13	Results	13
Median (Full Range)	Results	14
median	BAO:0002174	0-6
range	LABO:0000114	13-18
Unit of Measure: g/cm^2  -0.021        (-0.180 to 0.064)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 1/33 (3.03%)	Adverse Events	1
Pain - Head/Headache 1/33 (3.03%)	Adverse Events	2
pain	HP:0012531	0-4
Urticaria (hives, welts, wheals) 1/33 (3.03%)	Adverse Events	3
urticaria	HP:0001025,DOID:1555	0-9
Pruritus / Itching 1/33 (3.03%)	Adverse Events	4
pruritus	HP:0000989,GO:0160025	0-8
Adverse Events 2:	Adverse Events	5
Total: 0/16 (0.00%)	Adverse Events	6
Pain - Head/Headache 0/16 (0.00%)	Adverse Events	7
pain	HP:0012531	0-4
Urticaria (hives, welts, wheals) 0/16 (0.00%)	Adverse Events	8
urticaria	HP:0001025,DOID:1555	0-9
Pruritus / Itching 0/16 (0.00%)	Adverse Events	9
pruritus	HP:0000989,GO:0160025	0-8
